Dundar Tolga Turan, Hatiboglu Mustafa Aziz, Ergul Zehragul, Seyithanoglu Mehmet Hakan, Sozen Elif, Tuzgen Saffet, Kaynar Mehmet Yasar, Karaoz Erdal
Department of Neurosurgery, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Center for Regenerative Medicine and Stem Cell Research and Manufacturing, Liv Hospital, Istanbul, Turkey.
J Clin Med Res. 2019 Jun;11(6):415-421. doi: 10.14740/jocmr3781. Epub 2019 May 10.
Glioblastoma (GBM) is the most aggressive and the most common primary brain tumor. Over the last few years, studies have identified many genetical and phenotypical molecular situations for developing new treatment modalities in patients with GBM. Nevertheless, main problem for the GBM is radio-chemotherapy resistance and relapse after the surgery. The identification of glioma stem cells and microenvironmental influences has created a paradigm shift in targets of therapy. Current studies have shown that glioma stem cell is responsible for aggressiveness, recurrence and resistance to therapy of GBM. GBM stem cell isolated from human GBM multiforme fresh tissue samples is important both for curative therapeutic options and personalized targeted therapy. The purpose of this study was to determine the most suitable isolation method of GBM stem cells (GSCs).
Tumor tissue sample was obtained during the surgical resection of lesion in patients with the diagnosis of GBM. Tumor stem cell isolation from tissue was performed in three different ways: 1) GBM cell isolation with trypsin; 2) GBM cell isolation with brain tumor dissociation Kit (BTD Kit); and 3) GBM cell isolation with tumor dissociation enzyme (TDE).
We showed that GSCs were isolated from tumor specimen using flow cytometry and immunofluorescence staining. Our study showed that isolation with BTD Kit is the most suitable method to isolate GBM tissue-derived glial tumor stem cells.
The development of alternative personalized therapies targeting brain tumor stem cell is urgently needed. It is important to understand the fundamental mechanisms of driving stem cells. If their life cycle mechanisms can be identified, we can control the growth of GBM.
胶质母细胞瘤(GBM)是最具侵袭性且最常见的原发性脑肿瘤。在过去几年中,研究已确定了许多基因和表型分子情况,以开发针对GBM患者的新治疗模式。然而,GBM的主要问题是放化疗耐药性和术后复发。胶质瘤干细胞的鉴定和微环境影响在治疗靶点方面引发了范式转变。目前的研究表明,胶质瘤干细胞是GBM侵袭性、复发和治疗耐药的原因。从人多形性胶质母细胞瘤新鲜组织样本中分离出的GBM干细胞对于根治性治疗选择和个性化靶向治疗都很重要。本研究的目的是确定最适合的GBM干细胞(GSCs)分离方法。
在对诊断为GBM的患者进行病变手术切除期间获取肿瘤组织样本。从组织中分离肿瘤干细胞有三种不同方法:1)用胰蛋白酶分离GBM细胞;2)用脑肿瘤解离试剂盒(BTD试剂盒)分离GBM细胞;3)用肿瘤解离酶(TDE)分离GBM细胞。
我们表明,使用流式细胞术和免疫荧光染色从肿瘤标本中分离出了GSCs。我们的研究表明,用BTD试剂盒分离是分离GBM组织来源的胶质肿瘤干细胞的最合适方法。
迫切需要开发针对脑肿瘤干细胞的替代个性化疗法。了解驱动干细胞的基本机制很重要。如果能确定它们的生命周期机制,我们就能控制GBM的生长。